drugset / Trial / NCT06206720

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

NCT06206720

Phase 2 Completed 60 enrolled Vigonvita Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety, efficacy, pharmacokinetic (PK) characteristics and antiviral activity of different doses of Deuterium Hydrobromide for suspension in the treatment of respiratory syncytial virus infection in infants.

Timeline

Start
2024-01-31
Primary completion
2025-06-16
Completion
2025-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject REMIDEVIR Small molecule 15 mg/kg Oral
Subject REMIDEVIR Small molecule 20 mg/kg Oral